Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

SELL
$15.96 - $23.15 $175 - $254
-11 Reduced 0.04%
30,733 $560,000
Q3 2022

Nov 10, 2022

SELL
$23.23 - $30.07 $139 - $180
-6 Reduced 0.02%
30,744 $804,000
Q2 2022

Aug 10, 2022

BUY
$17.23 - $37.73 $529,822 - $1.16 Million
30,750 New
30,750 $779,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $950M
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track 1492 Capital Management LLC Portfolio

Follow 1492 Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 1492 Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on 1492 Capital Management LLC with notifications on news.